Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: January 27, 2009

CRi to Distribute VisEn Medical's Portfolio of Fluorescence In Vivo Imaging Agents and Labels in North America

(Nanowerk News) Cambridge Research & Instrumentation, Inc (CRi) and VisEn Medical announced today that they have signed a non-exclusive agreement to enable CRi to distribute VisEn's proprietary portfolio of fluorescent imaging agents and labels in North America. The distribution partnership is designed to broaden and extend today's leading fluorescence in vivo imaging technologies, applications and standards in research and drug development.
"With a deep heritage in multi-spectral fluorescence in vivo imaging and fluorescence microscopy imaging systems, we have built a significant customer base with a broad range of applications in life science research today. Bringing VisEn's fluorescent in vivo agents and labels to our Maestro™ multispectral fluorescence imaging system customers now expands the breadth of research for them, and for CRi," said George Abe, CRi's President and CEO. "We are pleased to be partnering with VisEn around their unparalleled agent products, and we look forward to continually expanding today's areas of in vivo research together."
VisEn's proprietary in vivo imaging agents and labels are designed to provide a robust and broad range of biologically-specific imaging readouts in vivo. VisEn now offers over 25 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways in vivo, with several more new agents expected for launch in 2009. Key research areas enabled by the VisEn agents include imaging disease progression and therapeutic response in real time in oncology, inflammation, cardiovascular disease, bone disease, and pulmonary diseases, all in the context of the living animal. VisEn also offers its specialized in vivo agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes for custom in vivo agent development, and its NanoSpark® in vivo labeling nanoparticles, all designed and optimized specifically for superior brightness, biocompatibility, stability and results in in vivo imaging. VisEn's agents and labels are designed to be compatible with a range of fluorescence imaging systems, including the CRi Maestro™ system with its powerful proprietary multispectral imaging technology. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.
"We are pleased to be working with CRi to further extend the applications and markets for our collective suite of fluorescence imaging technologies," said Kirtland Poss, President and CEO of VisEn Medical. "With several applications already developed in oncology and inflammation using the VisEn agents on the Maestro platforms, we look forward to working with CRi in rapidly expanding today's research areas in fluorescence imaging in vivo."
Source: CRi (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
 
 
If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!
 
 
These articles might interest you as well: